| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 98.173 | 7.791 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 98.173 | 7.791 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 93.081 | 50.937 | 0 | 0 | 0 | 0 | 0 | 7.458 | 0 | 2 |
| Gross Profit/Loss - EUR | 5.092 | -43.146 | 0 | 0 | 0 | 0 | 0 | -7.458 | 0 | -2 |
| Net Profit/Loss - EUR | 4.274 | -43.380 | 0 | 0 | 0 | 0 | 0 | -7.458 | 0 | -2 |
| Employees | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Sensipharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 179.453 | 5.780 | 5.682 | 5.578 | 5.470 | 5.367 | 5.248 | -96 | -96 | -95 |
| Inventories | 17.463 | 5.853 | 5.754 | 5.648 | 5.539 | 5.434 | 5.313 | 0 | 0 | 0 |
| Receivables | 135.384 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash | 26.606 | -72 | -71 | -70 | -68 | -67 | -66 | -96 | -96 | -95 |
| Shareholders Funds | 62.059 | -20.496 | -20.149 | -19.779 | -19.396 | -19.028 | -18.606 | -26.122 | -26.043 | -25.899 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 117.394 | 26.276 | 25.831 | 25.357 | 24.866 | 24.395 | 23.854 | 26.026 | 25.947 | 25.803 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Sensipharma S.r.l.